Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (EP3383418) SLC45A2 PEPTIDES FOR IMMUNOTHERAPY

Office : European Patent Office
Application Number: 16871668 Application Date: 02.12.2016
Publication Number: 3383418 Publication Date: 10.10.2018
Publication Kind : A4
Designated States: AL, AT, BA, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Prior PCT appl.: Application Number:US2016064825 ; Publication Number: Click to see the data
IPC:
A61K 38/00
A61K 39/00
A61P 35/00
C07K 11/00
C07K 14/435
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
11
Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
CPC:
C07K 14/70539
A61K 9/0019
A61K 9/0043
A61K 35/17
A61K 38/00
A61K 39/00
A61K 39/00119
A61K 45/06
A61K 2039/876
A61P 35/00
C12N 5/0638
Applicants: UNIV TEXAS
Inventors: LIZEE GREGORY
YEE CASSIAN
HWU PATRICK
ROSZIK JANOS
Priority Data: 201562263189 04.12.2015 US
201562263835 07.12.2015 US
2016064825 02.12.2016 US
Title: (DE) SLC45A2-PEPTIDE FÜR IMMUNTHERAPIE
(EN) SLC45A2 PEPTIDES FOR IMMUNOTHERAPY
(FR) PEPTIDES SLC45A2 POUR L'IMMUNOTHÉRAPIE
Abstract:
(EN) Provided are SLC45A2 peptides that bind to MHC I (HLA-A2) on melanoma cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells. The SLC45 A2 peptides may be therapeutically used to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.
(FR) L'invention concerne des peptides SLC45A2 qui se lient au CMH I (HLA-A2) sur des cellules de mélanome ou d'autres cellules présentatrices d'antigène, et qui sont reconnus par des récepteurs des lymphocytes T sur des lymphocytes T. Les peptides SLC45A2 peuvent être utilisés en thérapeutique pour traiter un cancer, par exemple un mélanome cutané, un mélanome uvéal, un mélanome muqueux ou un mélanome métastatique. L'invention concerne également des procédés de multiplication d'une population de lymphocytes T qui ciblent les peptides SLC45A2.
Also published as:
AU2016363006CA3007301SG11201804648RIL259793CN108601811KR1020180118105
US20190169262WO/2017/096304